复方苦参注射液联合奥沙利铂亚叶酸钙与氟尿嘧啶方案治疗中晚期结直肠癌的临床观察 |
| |
引用本文: | 周景祥,何培生,马亚玲,周小平,何东林. 复方苦参注射液联合奥沙利铂亚叶酸钙与氟尿嘧啶方案治疗中晚期结直肠癌的临床观察[J]. 中国肿瘤临床与康复, 2013, 0(10): 1141-1143 |
| |
作者姓名: | 周景祥 何培生 马亚玲 周小平 何东林 |
| |
作者单位: | [1]重庆三峡中心医院普外一科,重庆404100 [2]重庆三峡中心医院普外二科,重庆404100 [3]重庆三峡中心医院门诊,重庆404100 |
| |
摘 要: | 目的探讨复方苦参联合奥沙利铂亚叶酸钙与氟尿嘧啶(FOLFOX4)方案治疗中晚期结直肠癌的临床疗效、不良反应及预后评价。方法选择我院收治的84例中晚期结直肠癌患者,依据化疗方案不同分为研究组(41例)采用复方苦参联合FOLFOX4方案化疗;对照组(43例)采用FOLFOX4方案化疗。1个疗程为14d,治疗4个疗程后,比较两组近期疗效及不良反应。随访1年后,比较两组患者的预后。结果研究组和对照组患者的总有效率(OR)分别为43.9%和32.6%(P=0.034),部分缓解率(PR)分别为41.5%和30.2%(P=0.030),两组差异有统计学意义。两组患者完全缓解率(CR)分别为2.4%和2.3%(P=0.124),KPS评分有效率分别为65.9%和32.6%(P=0.012)。研究组患者的胃肠道反应、肝功能损害、白细胞下降、神经系统毒性等不良反应发生率较低(P〈0.05)。随访1年,研究组和对照组患者的生存率分别为17.1%和9.3%,差异有统计学意义(P=0.038)。结论复方苦参联合奥沙利铂治疗中晚期结直肠癌的临床疗效显著,不良反应较少,患者预后改善。
|
关 键 词: | 复方苦参注射液 FOLFOX4方案 结直肠肿瘤 药物疗法 |
The clinical effect of compound matrine injection combined with oxaliplatin on the adjuvant chemo- therapy of advanced colorectal cancer |
| |
Affiliation: | ZHOU Jin-xiang, HE Pei-sheng , MA Ya-lin , et al ( 1. The No. 1 General Surgical Department of Sanxia Central Hospital; 2. The No. 2 General Surgical Department; 3. The Out-patient Department, Chongqin 404100, China) |
| |
Abstract: | Objective To evaluate the clinical effect, side effects and prognosis of compound matrine injection combined with the FOLFOX4 scheme on the adjuvant chemotherapy of advanced colorectal cancer. Methods A total of 84 patients with advanced colorectal cancer were divided into two groups, research group (41 cases, application with compound matrine injection combined with FOLFOX4 scheme) and control group (43 cases, application with FOLFOX4 scheme), based on distinct chemotherapies. The chemotherapy was repeated every 14 days. Efficacy and toxicities were reviewed after 4 cycles of chemotherapy. And after one year follow-up, the index of prognosis, such as survival rate, was analyzed. Results Com- pared to control group, the rates of overall response (OR) and partial response (PR) were higher, 43.9% vs 32. 6% (P =0. 034), 41.5% vs 30. 2% (P =0. 030), but the rate of complete response (CR) was no different between two groups, 2.4% vs 2. 3% (P = 0. 124). The effective rate of KlX3 score in research group was higher than in control group[65.9% vs 32. 6% (P =0. 012) ]. The incidence rates of gastrointestinal reaction, liver dysfunction, leukopenia, nervous system toxicity in research group was lower than in control group (P 〈 0. 05 ). After one year follow-up, the survival rate in research group were better thancontrol group[ 17. 1% vs 9. 3 % (P = 0. 038 ) ]. Conclusions The combination of compound matrine injection and FOLFOX4 scheme was better effective, less side effects and better prognosis in advanced eolorectal cancer for adjuvant chemotherapy. |
| |
Keywords: | Compound matrine injection The FOLFOX4 scheme Colorectal neoplasms Drug therapy |
本文献已被 维普 等数据库收录! |
|